Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 15;24(1):96.
doi: 10.1186/s12883-024-03588-1.

Defining clinical endpoints in limb girdle muscular dystrophy: a GRASP-LGMD study

Amy Doody  1 , Lindsay Alfano  2 , Jordi Diaz-Manera  3 , Linda Lowes  2 , Tahseen Mozaffar  4 , Katherine D Mathews  5 , Conrad C Weihl  6 , Matthew Wicklund  7 , Man Hung  8 , Jeffrey Statland  9 , Nicholas E Johnson  10 ; GRASP-LGMD Consortium
Collaborators, Affiliations

Defining clinical endpoints in limb girdle muscular dystrophy: a GRASP-LGMD study

Amy Doody et al. BMC Neurol. .

Abstract

Background: The Limb Girdle Muscular Dystrophies (LGMDs) are characterized by progressive weakness of the shoulder and hip girdle muscles as a result of over 30 different genetic mutations. This study is designed to develop clinical outcome assessments across the group of disorders.

Methods/design: The primary goal of this study is to evaluate the utility of a set of outcome measures on a wide range of LGMD phenotypes and ability levels to determine if it would be possible to use similar outcomes between individuals with different phenotypes. We will perform a multi-center, 12-month study of 188 LGMD patients within the established Genetic Resolution and Assessments Solving Phenotypes in LGMD (GRASP-LGMD) Research Consortium, which is comprised of 11 sites in the United States and 2 sites in Europe. Enrolled patients will be clinically affected and have mutations in CAPN3 (LGMDR1), ANO5 (LGMDR12), DYSF (LGMDR2), DNAJB6 (LGMDD1), SGCA (LGMDR3), SGCB (LGMDR4), SGCD (LGMDR6), or SGCG (LGMDR5, or FKRP-related (LGMDR9).

Discussion: To the best of our knowledge, this will be the largest consortium organized to prospectively validate clinical outcome assessments (COAs) in LGMD at its completion. These assessments will help clinical trial readiness by identifying reliable, valid, and responsive outcome measures as well as providing data driven clinical trial decision making for future clinical trials on therapeutic agents for LGMD. The results of this study will permit more efficient clinical trial design. All relevant data will be made available for investigators or companies involved in LGMD therapeutic development upon conclusion of this study as applicable.

Trial registration: Clinicaltrials.gov NCT03981289; Date of registration: 6/10/2019.

Keywords: Clinical outcome assessments; Clinical trials; Limb girdle muscular dystrophy; Muscular dystrophy; Therapeutic development.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
GRASP-LGMD Consortium participating institutions. Adapted from Wikimedia Commons [40, 41]
See this image and copyright information in PMC

Update of

References

    1. Angelini CLGMD. Identification, description, and classification. Acta Myol. 2020;39(4):207–17. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783424/. Cited 7 Jul 2022. - PMC - PubMed
    1. Deenen JCW, Horlings CGC, Verschuuren JJGM, Verbeek ALM, van Engelen BGM. The epidemiology of neuromuscular disorders: a comprehensive overview of the literature. J Neuromuscul Dis. 2015;2(1):73–85. doi: 10.3233/JND-140045. - DOI - PubMed
    1. Moore SA, Shilling CJ, Westra S, Wall C, Wicklund MP, Stolle C, et al. Limb-girdle muscular dystrophy in the United States. J Neuropathol Exp Neurol. 2006;65(10):995–1003. doi: 10.1097/01.jnen.0000235854.77716.6c. - DOI - PubMed
    1. Nallamilli BRR, Chakravorty S, Kesari A, Tanner A, Ankala A, Schneider T, et al. Genetic landscape and novel disease mechanisms from a largeLGMDcohort of 4656 patients. Ann Clin Transl Neurol. 2018;5(12):1574–1587. doi: 10.1002/acn3.649. - DOI - PMC - PubMed
    1. Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Nusinersen versus Sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378(7):625–635. doi: 10.1056/NEJMoa1710504. - DOI - PubMed

MeSH terms

Associated data